Abstract

Alkermes PLC will release its second-quarter 2026 results Pre-MKt on July 28, 2026; this preview synthesizes company guidance proxies, consensus forecasts, and recent institutional commentary to frame revenue, margins, EPS, and business-mix dynamics for the quarter.

Market Forecast

Consensus for the second quarter of 2026 points to revenue of 457.62 million US dollars, up 33.98% year over year, with EBIT estimated at 17.94 million US dollars (down 58.03% year over year) and EPS at -0.03 (down 106.72% year over year). Margin expectations embed heavier operating expense timing and product mix effects; adjusted EPS is modeled near breakeven while gross margin is expected to remain high given the product mix, though specific gross margin guidance for the quarter is not available.

The company’s product portfolio remains the primary revenue engine, supported by stable manufacturing and royalty revenue; the outlook emphasizes continued uptake of proprietary therapies and steady contract revenues. The most promising segment is Products, net, which accounted for 338.11 million US dollars last quarter and is positioned for further year-over-year expansion as prescriptions scale; Manufacturing and royalty provided 54.80 million US dollars and is expected to contribute steady, lower-volatility inflows.

Last Quarter Review

The first quarter of 2026 delivered revenue of 392.91 million US dollars (up 28.19% year over year), a gross profit margin of 87.57%, GAAP net profit attributable to the parent company of -66.48 million US dollars, a net profit margin of -16.92%, and adjusted EPS of -0.40 (down 249.25% year over year). The quarter-on-quarter change in net profit registered -234.74%, reflecting a swing to a deeper loss as expense phasing and investment timing outweighed growth in top line.

Main business highlights showed Products, net at 338.11 million US dollars and Manufacturing and royalty at 54.80 million US dollars; the mix favored proprietary products, which continued to expand their share of total revenue alongside predictable contract-manufacturing and royalty streams.

Current Quarter Outlook

Main business momentum

The principal driver this quarter remains the Products, net franchise. The prior quarter’s 338.11 million US dollars contribution demonstrates durable demand across key therapies, with revenue concentration in proprietary brands supporting strong gross margin performance. This momentum, coupled with the consensus revenue forecast of 457.62 million US dollars for the current quarter, suggests the core portfolio is tracking to a healthy year-over-year expansion of 33.98% even as operating costs pressure near-term profitability metrics. The portfolio mix should maintain gross margin quality, though EBIT and EPS forecasts point to elevated commercial and R&D outlays, which will be central to the quarterly narrative.

Most promising business

Products, net is positioned as the company’s most promising growth vector for the quarter. The scale reached last quarter, at 338.11 million US dollars, indicates that prescription volume and pricing continue to be supportive, and this unit’s leverage typically sustains high gross margins. The growth trajectory into the second quarter aligns with the consensus revenue uplift, implying that proprietary products will again be the dominant source of incremental revenue. While the EBIT forecast of 17.94 million US dollars reflects tightening operating leverage, the revenue cadence from the product franchise is expected to anchor near-term growth and provide an avenue for operating efficiency improvement in the second half if spending normalization occurs.

Key stock-price swing factors

The first determinant is revenue quality versus headline growth: markets will parse whether the second-quarter revenue beat or miss, if any, is driven by sustainable prescription demand in proprietary products or by one-time items in contract manufacturing and royalties. The second factor is operating expense timing; the EBIT estimate declining 58.03% year over year alongside an EPS estimate of -0.03 implies heavier spend, and any deviation—either lower-than-expected commercial or R&D outlays, or delayed spend—could translate into a notable EPS variance. The third factor is gross margin stability; last quarter’s 87.57% underscores the mix advantage, and investors will watch for any dilution from segment mix or inventory dynamics, as even modest changes at this margin level can move EBIT disproportionately.

Analyst Opinions

Across recently captured institutional commentary, the balance of views trends constructive on near-term revenue resilience and product-led growth, while acknowledging EPS sensitivity to expense timing; the ratio of bullish to bearish opinions skews positive. Analysts highlighting the quarter emphasize that consensus revenue growth of 33.98% year over year is underpinned by continued demand for proprietary therapies, with Manufacturing and royalty revenue providing a stabilizing base that can mitigate volatility in product uptake. Well-known institutional voices point to the combination of high gross margins and scaling product revenue as supportive for medium-term operating leverage, even if near-term EBIT and EPS are dampened by planned investments. The majority view expects the company to deliver on top-line growth with a clear path to margin normalization as spending levels plateau, framing potential upside to EPS if operating expenses land below modeled levels or if product mix tilts further toward higher-margin assets.